Press Release

July 2, 2018
Verastem Oncology to Participate in the Oppenheimer Boston Oncology Insight Summit

BOSTON--(BUSINESS WIRE)--Jul. 2, 2018-- Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will participate in the Oppenheimer Boston Oncology Insight Summit on July 10-11, 2018, in Boston, Massachusetts. The two-day event will feature oncology-focused companies and will consist of one-on-one meetings with institutional investors preceded by a Lecture Series from members of the Whitehead Institute in Cambridge, Massachusetts.

Members of Verastem Oncology’s executive team will participate in the event. To learn more about the event please visit the following link: https://www.opco.com/conferences/oncology18/index.aspx.

About Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in indolent Non-Hodgkin Lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Verastem Oncology’s New Drug Application (NDA) requesting the full approval of duvelisib for the treatment of patients with relapsed or refractory CLL/SLL, and accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma (FL) was accepted for filing by the U.S. Food and Drug Administration (FDA), granted Priority Review and assigned a target action date of October 5, 2018. In addition, Verastem Oncology is developing the focal adhesion kinase (FAK) inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small-cell lung cancer (NSCLC), and mesothelioma. Verastem Oncology’s product candidates seek to treat cancer by modulating the local tumor microenvironment and enhancing anti-tumor immunity. For more information, please visit www.verastem.com.

Source: Verastem, Inc.

Verastem Oncology, Inc.
Marianne M. Lambertson, +1-781-292-4273
Vice President, Corporate Communications
Investor Relations/Public Relations
mlambertson@verastem.com